FINWIRES · TerminalLIVE
FINWIRES

Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target

By

EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $40.50, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles